Literature DB >> 20167217

Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males.

Sverre Söderlund1, Fredrik Granath, Olle Broström, Per Karlén, Robert Löfberg, Anders Ekbom, Johan Askling.   

Abstract

BACKGROUND & AIMS: Reported differences in cancer risk between male and female animals after chronic inflammation suggest that estrogen has inflammation-modifying properties. Little is known about these effects in human beings. Inflammatory bowel disease (IBD) is associated with an increased risk of colorectal cancer (CRC); we studied differences in inflammation-associated CRC between men and women patients with IBD.
METHODS: By using a large population-based cohort (n = 7607) of individuals diagnosed with IBD from 1954 to 1989, we assessed the sex-specific incidence of CRC from 1960 to 2004. Incidence was determined within the cohort (modeled using Poisson regression) and compared with the general population (assessed as standardized incidence ratios) using data from national Swedish health and census registers.
RESULTS: During 171,000 person-years of follow-up evaluation, 196 new cases of CRC were observed (123 in males, 73 in females). Males with IBD had a 60% higher risk of CRC (relative risk [RR], 1.6; 95% confidence interval [CI], 1.2-2.2) than females (cumulative incidence 40 years after IBD diagnosis, 8.3% vs 3.5%). Compared with the rate of CRC among the general population, in males with IBD the RR was 2.6 and the 95% CI was 2.2-3.1, whereas in females the RR was 1.9 and the 95% CI was 1.5-2.4. The effect of sex was limited to the period after 10 years of follow-up evaluation (RR, 0.8 before vs 2.2 after), and to patients diagnosed before age 45 (RR, 2.1 before vs 1.0 after).
CONCLUSIONS: IBD confers a lower risk of CRC to females than to males. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20167217     DOI: 10.1053/j.gastro.2010.02.007

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  38 in total

1.  Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis.

Authors:  Sundaram Ramasamy; Deanna D Nguyen; Michelle A Eston; Sayeda Nasrin Alam; Angela K Moss; Farzad Ebrahimi; Brishti Biswas; Golam Mostafa; Kathryn T Chen; Kanakaraju Kaliannan; Halim Yammine; Sonoko Narisawa; José Luis Millán; H Shaw Warren; Elizabeth L Hohmann; Emiko Mizoguchi; Hans-Christian Reinecker; Atul K Bhan; Scott B Snapper; Madhu S Malo; Richard A Hodin
Journal:  Inflamm Bowel Dis       Date:  2011-02       Impact factor: 5.325

Review 2.  Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences.

Authors:  Amosy E M'Koma; Harold L Moses; Samuel E Adunyah
Journal:  Int J Colorectal Dis       Date:  2011-02-11       Impact factor: 2.571

3.  A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma.

Authors:  Karen S Yee; Lukasz Grochola; Garth Hamilton; Anna Grawenda; Elisabeth E Bond; Helge Taubert; Peter Wurl; Gareth L Bond; Eric O'Neill
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

4.  Transmission distortion in Crohn's disease risk gene ATG16L1 leads to sex difference in disease association.

Authors:  Linda Y Liu; Marc A Schaub; Marina Sirota; Atul J Butte
Journal:  Inflamm Bowel Dis       Date:  2011-05-25       Impact factor: 5.325

5.  Ratio of Circulating Estrogen Receptors Beta and Alpha (ERβ/ERα) Indicates Endoscopic Activity in Patients with Crohn's Disease.

Authors:  Pablo M Linares; Alicia Algaba; Ana Urzainqui; Mercedes Guijarro-Rojas; Rafael González-Tajuelo; Jesús Garrido; María Chaparro; Javier P Gisbert; Fernando Bermejo; Iván Guerra; Víctor Castellano; María-Encarnación Fernández-Contreras
Journal:  Dig Dis Sci       Date:  2017-08-19       Impact factor: 3.199

Review 6.  The Natural History of IBD: Lessons Learned.

Authors:  Petra Weimers; Pia Munkholm
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03

7.  Advances in the Diagnosis and Management of Colonic Dysplasia in Patients With Inflammatory Bowel Disease.

Authors:  Shirley Cohen-Mekelburg; Yecheskel Schneider; Stephanie Gold; Ellen Scherl; Adam Steinlauf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-06

8.  Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey.

Authors:  Nalan Gülşen Ünal; Ömer Özütemiz; Fatih Tekin; İlker Turan; Necla Osmanoğlu
Journal:  Turk J Gastroenterol       Date:  2019-02       Impact factor: 1.852

Review 9.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

10.  Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics.

Authors:  Daniel D Buchanan; Kevin Sweet; Musa Drini; Mark A Jenkins; Aung Ko Win; Dallas R English; Michael D Walsh; Mark Clendenning; Diane M McKeone; Rhiannon J Walters; Aedan Roberts; Sally-Ann Pearson; Erika Pavluk; John L Hopper; Michael R Gattas; Jack Goldblatt; Jill George; Graeme K Suthers; Kerry D Phillips; Sonja Woodall; Julie Arnold; Kathy Tucker; Amanda Muir; Michael Field; Sian Greening; Steven Gallinger; Renee Perrier; John A Baron; John D Potter; Robert Haile; Wendy Frankel; Albert de la Chapelle; Finlay Macrae; Christophe Rosty; Neal I Walker; Susan Parry; Joanne P Young
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.